BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Jan 16, 15:52Prev. Close
25.84
Open Price
25.84
Bid Price (Qty.)
24.92 (10)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Balaxi Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 8.64 | 6.47 | -2.53 | -2.60 | -0.26 | |
| Diluted EPS (Rs.) | 8.64 | 6.47 | -2.53 | -2.60 | -0.26 | |
| Cash EPS (Rs.) | 6.50 | 6.48 | -2.53 | -2.59 | -0.26 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 28.11 | 11.58 | 5.11 | 7.76 | 10.36 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 28.11 | 11.58 | 5.11 | 7.76 | 10.36 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 45.63 | 44.72 | 0.00 | -2.02 | 0.16 | |
| PBDIT/Share (Rs.) | 9.27 | 8.04 | -2.53 | -2.46 | -0.22 | |
| PBIT/Share (Rs.) | 9.27 | 8.02 | -2.53 | -2.46 | -0.23 | |
| PBT/Share (Rs.) | 9.27 | 8.02 | -2.53 | -2.60 | -0.38 | |
| Net Profit/Share (Rs.) | 6.50 | 6.47 | -2.53 | -2.60 | -0.26 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.32 | 17.96 | 0.00 | 121.56 | -142.73 | |
| PBIT Margin (%) | 20.30 | 17.94 | 0.00 | 121.79 | -147.33 | |
| PBT Margin (%) | 20.30 | 17.94 | 0.00 | 128.49 | -244.81 | |
| Net Profit Margin (%) | 14.23 | 14.46 | 0.00 | 128.49 | -169.16 | |
| Return on Networth / Equity (%) | 23.10 | 55.84 | -49.52 | -33.46 | -2.55 | |
| Return on Capital Employed (%) | 32.95 | 69.28 | -49.52 | -31.72 | -2.55 | |
| Return on Assets (%) | 17.13 | 32.18 | -45.64 | -30.64 | -2.25 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | |
| Asset Turnover Ratio (%) | 120.38 | 222.59 | 0.00 | -23.84 | 1.33 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 3.75 | 2.23 | 12.47 | 11.67 | 0.61 | |
| Quick Ratio (X) | 3.66 | 2.23 | 12.47 | 11.67 | 0.61 | |
| Inventory Turnover Ratio (X) | 54.84 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 70.43 | 11.42 | 2.85 | 3.14 | 4.01 | |
| EV/Net Operating Revenue (X) | 1.54 | 0.84 | 0.00 | -5.11 | 84.45 | |
| EV/EBITDA (X) | 7.60 | 4.67 | -3.72 | -4.20 | -59.16 | |
| MarketCap/Net Operating Revenue (X) | 1.62 | 0.85 | 0.00 | -8.86 | 80.30 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 2.63 | 3.28 | 2.89 | 2.31 | 1.21 | |
| Price/Net Operating Revenue | 1.62 | 0.85 | 0.00 | -8.86 | 80.45 | |
| Earnings Yield | 0.09 | 0.17 | -0.17 | -0.15 | -0.02 |
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
15.06.2017
24.04.2017
18.04.2017
18.04.2017
14.02.2017
13.02.2017
12.02.2017
09.12.2016